Compare BioNano Genomics Inc (BNGO) vs MasTec Inc (MTZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs MasTec Inc — how do they compare? BioNano Genomics Inc trades at $1.2 (market cap $13.66M), while MasTec Inc trades at $281.27 (market cap $21.90B). The key difference: MasTec Inc is far larger — about 1603.2× BioNano Genomics Inc's market cap, and MasTec Inc is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.
| BNGO | MTZ | |
|---|---|---|
Market Cap | $13.66M | $21.90B |
Sector | Health | Technology |
52-Week High | $4.92 | $437.51 |
52-Week Low | $1.06 | $172.51 |
Enterprise Value | $16.26M | $24.81B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.195, up 3.02% today, with a bullish technical signal from moving averages but a neutral oscillator stance. The company shows improving financial trends, with net losses narrowing to -$26.40M in 2025 from -$232M in 2023, and recent earnings beats. Revenue stabilized around $29M, while cash flow trends indicate reduced operational cash burn. Analyst sentiment is positive, with 57% buy ratings.
The outlook for BNGO hinges on sustaining revenue growth and achieving profitability, supported by strategic hires and debt retirement. Key risks include persistent negative margins and high cash burn. With a low P/S of 0.31, the stock offers value if execution improves, but investors face volatility from operational challenges and competitive pressures.
MTZ trades at $282.66, up 5.36% over 24 hours, with a bearish technical signal but strong fundamental momentum. The company reported record Q2 2026 revenue of $4.37 billion, up 23% year-over-year, and raised its full-year outlook, supported by a $21.4 billion backlog and recent acquisition of The Superior Group. Analyst consensus is overwhelmingly bullish with a $439.56 price target, though technical indicators show selling pressure near resistance at $283.
The outlook for MTZ is positive, driven by infrastructure demand and earnings beats, but risks include execution on large projects and debt from recent note issuance. The stock offers growth potential if it can sustain margin expansion and capitalize on its record backlog, though investors should monitor communications segment delays and interest expense impacts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About MasTec Inc
MasTec, Inc. is a leading infrastructure construction company operating mainly in North America. The company's services cover a diverse range of end-markets, including communications (building fiber and wireless infrastructure), oil & gas, electric power (transmission, distribution, and clean energy), and industrial projects. MTZ provides critical engineering, procurement, and construction (EPC) services that support the expansion and maintenance of essential infrastructure across the continent.
Read more on MTZ →
